After intraperitoneal (i.p.)or intravenous (i.v.)injection, STZ enters the pancreatic β-cell through the glucose transporter 2 transporter (Glut-2) resulting in hyperglycemia [16]. Here, SLC2A2 is linked to Hyperglycemia.